ImmuPharma PLC (AIM:IMM, OTC:IMMPF) has inked a two-year collaboration agreement with Imperial College London.
Under the terms of the tie-up, Imperial’s scientists “will provide significant intellectual input and guidance” on a number of peptide assets developed by the company’s Bordeaux-based subsidiary, ImmuPharma Biotech.
Chief operating officer, Dr Tim Franklin, said: "We are all extremely excited to be working with such a world-leading academic institute.
“This union will be invaluable in guiding and progressing our earlier stage product development portfolio, as well as enhancing our intellectual property base."